Muse Cell Clinical Trials: What Has Been Published and What It Means for Patients

The past fifteen years have seen a shift in how investigational regenerative therapies are studied in human volunteers. Among the cell types attracting clinical attention are Muse cells—multilineage-differentiating stress-enduring cells—originally characterized by Kuroda, Dezawa and colleagues in 2010. Since that early discovery work, a handful of early-phase trials have been published, most of them conducted in Japan under regulatory pathways that differ from those in the United States. For anyone considering investigational cell-based support, understanding what has actually been published, how to interpret trial endpoints, and what questions remain unanswered is essential. This article walks through the peer-reviewed Muse cells clinical trials available in the literature, explains the terminology that often confuses patients, and outlines the framework Dr. Charles Pereyra, MD uses when evaluating whether published evidence supports a particular investigational option.

What Are Muse Cells and Why Were They Studied in Trials?

Muse cells are a rare population of pluripotent-like cells found in adult tissues, identified by the surface marker SSEA-3 and initially described by Kuroda and colleagues (2010) in the Proceedings of the National Academy of Sciences. Wakao, Dezawa and others (2011) demonstrated that these cells, which make up roughly one percent of mesenchymal tissue, can differentiate into multiple lineages when placed in appropriate microenvironments. What drew clinical interest was not only their differentiation capacity but also their apparent ability to home to sites of tissue injury when delivered intravenously—a mechanism explored in detail by Yamada and colleagues (2018), who showed that the S1P–S1PR2 signaling axis guides systemically administered Muse cells toward damaged tissue in preclinical models.

That homing property suggested that intravenous infusion—rather than direct local injection—might be a feasible delivery route for investigational regenerative support. Beginning around 2015, Japanese investigators began enrolling patients into first-in-human safety studies, and the earliest published results appeared in peer-reviewed journals in 2020. Understanding the structure and interpretation of those trials helps patients and physicians separate rigorous evidence from speculative marketing.

The First-in-Human Trials: Noda 2020 and What "First-in-Human" Means

The phrase "first-in-human" refers to the initial phase of clinical testing in which an investigational agent is administered to people for the first time. These are typically small, open-label studies designed primarily to assess safety rather than efficacy. Noda and colleagues published one such study in Circulation Journal in 2020, describing intravenous administration of an allogeneic Muse cell product called CL2020 in a small cohort. The trial was conducted in Japan and focused on establishing that the infusion could be given without serious adverse events. It was not a randomized, placebo-controlled trial, and the endpoints were safety-oriented rather than measures of functional improvement.

What does that mean for patients? It means that the Noda 2020 study answered the question "Can this be given without causing immediate harm?" rather than "Does this produce a meaningful benefit?" First-in-human trials are essential stepping stones, but they do not provide the level of evidence needed to draw conclusions about effectiveness. The Japanese regulatory framework allowed this early-phase work to proceed more rapidly than might be typical under FDA oversight in the United States, which is one reason why most published Muse cells clinical trials have originated in Japan.

Randomized Controlled Trials: Niizuma 2023 and the Challenge of Mixed Results

After establishing preliminary safety, investigators moved toward randomized, double-blind, placebo-controlled trials—the gold standard for assessing whether an investigational therapy produces effects beyond placebo. Niizuma and colleagues published such a trial in Neurology in 2023, examining intravenous CL2020 in patients enrolled at multiple Japanese centers. This was a phase-two study, meaning it was designed to provide early signals of efficacy while continuing to monitor safety in a larger cohort than the first-in-human work.

The results were modest and not uniformly positive. While some secondary endpoints showed numerical trends favoring the cell group, the primary endpoint—the study's prespecified main measure—did not reach statistical significance. This is an important lesson in how to read clinical trial reports: not every published study is a success story, and investigational therapies in regenerative medicine often show mixed or inconsistent effects. Dr. Charles Pereyra emphasizes to patients that the scientific literature is not a collection of only positive findings; honest interpretation requires acknowledging when trials show weak or null signals.

The Niizuma 2023 trial illustrates why multiple studies, larger sample sizes, and replication across diverse populations are necessary before any investigational option can be considered established. One modest trial in one country under one regulatory pathway does not settle whether Muse cell infusion produces meaningful functional support. It adds a data point—an important one—but it is not definitive evidence.

Mechanism Studies: Yamada 2018 and the Biology of Cell Homing

While safety and efficacy trials answer whether an intervention can be given and whether it works, mechanism studies address how it might work. Yamada and colleagues (2018) published work in Circulation Research showing that intravenously delivered Muse cells are drawn toward damaged tissue through the sphingosine-1-phosphate receptor 2 (S1P–S1PR2) signaling pathway. When tissue is injured, local S1P gradients increase, and the Muse cells—which express the S1PR2 receptor—migrate along that gradient. This was demonstrated in preclinical models of acute injury and provided a biological rationale for why systemic infusion might target injury sites.

Mechanism studies like Yamada 2018 are crucial for understanding plausibility, but they do not replace human clinical trials. A pathway that functions in a controlled laboratory setting may behave differently in the complex environment of human disease. Still, this work strengthened the scientific foundation for pursuing Muse cell trials and helped investigators design dosing and timing protocols that align with the known biology of cell trafficking.

Comparing Muse Cells to Other Mesenchymal Cell Trials: Hare 2009 and Bartolucci 2017

To understand where Muse cells clinical trials fit within the broader landscape of regenerative cell therapy research, it is helpful to compare them to published trials of mesenchymal stem cells (MSCs), a more widely studied cell population. Hare and colleagues (2009) published a randomized trial in the Journal of the American College of Cardiology examining intravenous allogeneic MSCs in a cohort of patients enrolled shortly after a specific acute event. The trial was primarily a safety study, and it demonstrated that intravenous cell infusion could be performed without serious complications—an important proof-of-concept for systemic cell delivery.

Bartolucci and colleagues (2017) took the work further in the RIMECARD trial, published in Circulation Research, which examined umbilical-cord-derived MSCs in patients with chronic functional limitations. The trial reported modest improvements in certain functional metrics, with effect sizes on the order of several percentage points in key measures. These studies are not about Muse cells specifically, but they establish precedent for the idea that allogeneic, intravenously delivered cells can be studied in human volunteers without prohibitive safety concerns.

What distinguishes Muse cells from standard MSCs is the presence of pluripotent markers like SSEA-3 and the more robust in vitro differentiation capacity. Whether that translates to superior clinical outcomes remains an open question. The published Muse cells clinical trials to date (Noda 2020, Niizuma 2023) have smaller sample sizes and shorter follow-up periods than the larger MSC trials, so direct head-to-head comparisons are not yet possible.

How to Read a Muse Cell Trial: Phase Terminology, Endpoints, and Statistical Significance

One of the most common sources of confusion is trial phase terminology. Phase I trials test safety in small groups, often fewer than twenty participants, and are not designed to measure efficacy. Phase II trials enroll larger cohorts—often fifty to several hundred patients—and begin to look for signals of benefit while continuing to monitor safety. Phase III trials are large, multicenter, randomized studies intended to provide definitive evidence of efficacy and form the basis for regulatory approval. Most published Muse cells clinical trials are phase I or early phase II, meaning they are early-stage exploratory work rather than confirmatory studies.

Endpoints are the prespecified measures a trial uses to evaluate success. A primary endpoint is the single most important outcome; secondary endpoints are additional measures that may provide supporting evidence. When a trial reports that the primary endpoint was not met—as in the Niizuma 2023 study—it means the main question the trial was designed to answer did not yield a statistically significant result. That does not mean the intervention has no effect, but it does mean the evidence for benefit is weaker than if the primary endpoint had been positive.

Statistical significance is a threshold used to determine whether observed differences are likely due to the intervention or could plausibly arise from chance. A p-value less than 0.05 is the conventional cutoff, but that threshold is somewhat arbitrary. Small trials often lack the statistical power to detect modest effects, which is why negative or inconclusive early-phase trials do not necessarily rule out future positive findings in larger studies. Dr. Pereyra walks patients through these concepts when reviewing published trial data, emphasizing that individual responses vary and that early-stage evidence should be interpreted with appropriate caution.

The Japanese Regulatory Context and Why Most Trials Occurred There

Japan has a conditional approval pathway for regenerative medicine products that allows earlier market access than is typical under FDA rules in the United States. Under this framework, a sponsor can gain provisional approval based on early-phase safety data and limited efficacy signals, with the requirement to complete confirmatory trials post-approval. This regulatory structure accelerated the clinical development of CL2020, the Muse cell product used in the Noda 2020 and Niizuma 2023 trials, and is one reason why published Muse cells clinical trials have originated almost exclusively in Japan.

For patients in the United States, this raises important questions about generalizability. Japanese regulatory approval does not equate to FDA approval, and a therapy available in one country may not be available—or may not be supported by equivalent evidence—in another. That said, physician-supervised investigational Muse cell infusion is offered in some U.S. clinics under research or expanded-access frameworks, allowing patients to receive investigational support without travelling overseas. Dr. Pereyra evaluates candidacy on a case-by-case basis, taking into account the individual's medical history, the strength of the published evidence for their particular situation, and realistic expectations about what early-stage trials do and do not tell us.

What the Published Trials Do Not Tell Us

As valuable as the published Muse cells clinical trials are, they leave significant questions unanswered. Most of the trials enrolled patients within narrow time windows following acute events, so we have limited data on whether Muse cell infusion is relevant for chronic or slowly progressive conditions. The trials published to date have been conducted in Japanese populations, and it is not yet clear whether findings generalize across ethnic and genetic backgrounds. Long-term follow-up—beyond one or two years—has not been published for most cohorts, so durability of any observed effects remains uncertain.

Dose-response relationships are also poorly understood. The trials used specific cell doses, often in the range of millions to tens of millions of cells per infusion, but whether higher or lower doses, or repeated infusions, might alter outcomes has not been rigorously tested. Combination approaches—using Muse cells alongside other regenerative modalities like exosomes, platelet-rich plasma, or tissue engineering scaffolds—are largely unexplored in the published literature. These gaps are not criticisms of the work that has been done; they simply reflect the reality that clinical research in regenerative medicine is still in its early stages.

What Questions Should a Patient Ask Before Pursuing Investigational Muse Cell Therapy?

When Dr. Pereyra discusses investigational Muse cell options with patients, he emphasizes a set of core questions that help clarify what is known and what is speculative. Has the specific product being offered been studied in published peer-reviewed trials, or is it a variation without direct clinical evidence? What were the endpoints in those trials, and were they met? How does the proposed infusion protocol—dose, timing, frequency—compare to what was tested in the published studies?

Patients should also ask about safety monitoring. Even in trials that reported no serious adverse events, rigorous monitoring protocols were in place. An investigational infusion should include pre-infusion screening, real-time monitoring during the procedure, and structured follow-up to detect any delayed complications. Cost is another practical consideration; investigational therapies are rarely covered by insurance, and patients should have transparent information about out-of-pocket expense before proceeding.

Finally, it is essential to discuss realistic expectations. No investigational therapy has certain outcomes, and the published Muse cells clinical trials show modest, mixed results rather than dramatic transformations. Individual responses vary widely, and not all patients experience measurable benefit. A physician-led candidacy evaluation—taking into account overall health, concurrent conditions, and specific goals—is the appropriate starting point for determining whether investigational Muse cell support is a reasonable option.

Moving Forward: What Future Trials Might Tell Us

The trajectory of Muse cell research is likely to follow the pattern seen with other investigational cell therapies: incremental progress through larger, more rigorous trials, with some studies showing positive signals and others showing null or weak effects. Ongoing work registered on platforms like clinicaltrials.gov suggests that additional phase II and phase III trials are in planning or enrollment stages, though publication timelines remain uncertain.

Future trials may explore different patient populations, alternative dosing regimens, and combination approaches that incorporate Muse cells with other regenerative modalities. Mechanistic studies will continue to refine our understanding of how systemically delivered cells traffic to injury sites and what factors determine whether they engraft and contribute to tissue repair. As that evidence base grows, the questions that patients and physicians can answer with confidence will expand, and the role of Muse cell infusion within regenerative medicine will become clearer.

Until then, the published trials—Noda 2020, Niizuma 2023, and the mechanistic work by Yamada 2018, alongside the broader MSC trial literature represented by Hare 2009 and Bartolucci 2017—represent the best available evidence. That evidence is early-stage, cautiously optimistic, and incomplete. For patients exploring investigational options in the United States without the need to travel overseas, working with a physician who understands how to interpret trial data and set realistic expectations is essential. Dr. Pereyra's approach is rooted in that evidence-based framework: transparent about what is known, honest about what is not, and focused on individualized candidacy decisions rather than one-size-fits-all protocols.

Frequently Asked Questions About Muse Cells Clinical Trials

What is the difference between a safety trial and an efficacy trial?

Safety trials, often called phase I or first-in-human studies, are designed to determine whether an investigational intervention can be given without causing serious harm. They typically enroll small numbers of participants and do not include placebo controls. Efficacy trials, usually phase II or III, are larger randomized studies intended to measure whether the intervention produces meaningful benefit. The Noda 2020 study was primarily a safety trial, while Niizuma 2023 was an early efficacy trial with modest and mixed results.

Have Muse cells been approved by the FDA?

No. Muse cell products have received conditional approval in Japan under a regulatory pathway that allows earlier market access based on limited data, but they are not FDA-approved in the United States. Investigational access may be available through research protocols or expanded-access programs, but that does not mean the intervention has been proven effective or carries FDA endorsement. Patients considering investigational therapy should understand the difference between regulatory approval and investigational use.

Why do most published Muse cell trials come from Japan?

Japan's regenerative medicine regulatory framework allows conditional approval of investigational cell products based on early-phase data, which has enabled faster clinical development than is typical under FDA oversight. This accelerated pathway allowed the CL2020 Muse cell product to enter human trials earlier, which is why most published studies have been conducted in Japanese populations. Generalizability to other ethnic and genetic backgrounds remains an open question.

What should I look for when evaluating whether a clinic's Muse cell offering is evidence-based?

Ask whether the specific product has been studied in peer-reviewed published trials, and request copies of those publications. Verify that the proposed protocol—cell dose, infusion route, timing—matches what was tested in the published studies. Confirm that safety monitoring and follow-up are structured similarly to the trial protocols. Be wary of claims that go beyond what the published evidence supports, such as promises of specific functional improvements or success rates. A physician-supervised candidacy evaluation and transparent discussion of realistic expectations are essential.